These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 30404440)

  • 1. Antagonists for Constitutively Active Mutant Estrogen Receptors: Insights into the Roles of Antiestrogen-Core and Side-Chain.
    Sharma A; Toy W; Guillen VS; Sharma N; Min J; Carlson KE; Mayne CG; Lin S; Sabio M; Greene G; Katzenellenbogen BS; Chandarlapaty S; Katzenellenbogen JA
    ACS Chem Biol; 2018 Dec; 13(12):3374-3384. PubMed ID: 30404440
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structurally Novel Antiestrogens Elicit Differential Responses from Constitutively Active Mutant Estrogen Receptors in Breast Cancer Cells and Tumors.
    Zhao Y; Laws MJ; Guillen VS; Ziegler Y; Min J; Sharma A; Kim SH; Chu D; Park BH; Oesterreich S; Mao C; Shapiro DJ; Nettles KW; Katzenellenbogen JA; Katzenellenbogen BS
    Cancer Res; 2017 Oct; 77(20):5602-5613. PubMed ID: 28904064
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeted degradation of activating estrogen receptor α ligand-binding domain mutations in human breast cancer.
    Gonzalez TL; Hancock M; Sun S; Gersch CL; Larios JM; David W; Hu J; Hayes DF; Wang S; Rae JM
    Breast Cancer Res Treat; 2020 Apr; 180(3):611-622. PubMed ID: 32067153
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In silico identification of novel inhibitors targeting the DNA-binding domain of the human estrogen receptor alpha.
    Cao H; Sun Y; Wang L; Pan Y; Li Z; Liang Y
    J Steroid Biochem Mol Biol; 2021 Oct; 213():105966. PubMed ID: 34416373
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Suppression of breast cancer metastasis and extension of survival by a new antiestrogen in a preclinical model driven by mutant estrogen receptors.
    Laws MJ; Ziegler Y; Shahoei SH; Dey P; Kim SH; Yasuda M; Park BH; Nettles KW; Katzenellenbogen JA; Nelson ER; Katzenellenbogen BS
    Breast Cancer Res Treat; 2020 Jun; 181(2):297-307. PubMed ID: 32277377
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design and Synthesis of Novel Breast Cancer Therapeutic Drug Candidates Based upon the Hydrophobic Feedback Approach of Antiestrogens.
    Ohta K; Kaise A; Taguchi F; Aoto S; Ogawa T; Endo Y
    Molecules; 2019 Nov; 24(21):. PubMed ID: 31683895
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis and evaluation of tamoxifen derivatives with a long alkyl side chain as selective estrogen receptor down-regulators.
    Shoda T; Kato M; Harada R; Fujisato T; Okuhira K; Demizu Y; Inoue H; Naito M; Kurihara M
    Bioorg Med Chem; 2015 Jul; 23(13):3091-6. PubMed ID: 26003343
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stereospecific lasofoxifene derivatives reveal the interplay between estrogen receptor alpha stability and antagonistic activity in
    Hosfield DJ; Weber S; Li NS; Sauvage M; Joiner CF; Hancock GR; Sullivan EA; Ndukwe E; Han R; Cush S; Lainé M; Mader SC; Greene GL; Fanning SW
    Elife; 2022 May; 11():. PubMed ID: 35575456
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Estrogen receptor alpha somatic mutations Y537S and D538G confer breast cancer endocrine resistance by stabilizing the activating function-2 binding conformation.
    Fanning SW; Mayne CG; Dharmarajan V; Carlson KE; Martin TA; Novick SJ; Toy W; Green B; Panchamukhi S; Katzenellenbogen BS; Tajkhorshid E; Griffin PR; Shen Y; Chandarlapaty S; Katzenellenbogen JA; Greene GL
    Elife; 2016 Feb; 5():. PubMed ID: 26836308
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antiestrogen Resistant Cell Lines Expressing Estrogen Receptor α Mutations Upregulate the Unfolded Protein Response and are Killed by BHPI.
    Mao C; Livezey M; Kim JE; Shapiro DJ
    Sci Rep; 2016 Oct; 6():34753. PubMed ID: 27713477
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exploring the molecular basis of action of ring D aromatic steroidal antiestrogens.
    Alvarez LD; Veleiro AS; Burton G
    Proteins; 2015 Jul; 83(7):1297-306. PubMed ID: 25921217
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular mechanisms of estrogen action: selective ligands and receptor pharmacology.
    Katzenellenbogen BS; Choi I; Delage-Mourroux R; Ediger TR; Martini PG; Montano M; Sun J; Weis K; Katzenellenbogen JA
    J Steroid Biochem Mol Biol; 2000 Nov; 74(5):279-85. PubMed ID: 11162936
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A new class of 1,3,5-triazine-based selective estrogen receptor degraders (SERDs): Lead optimization, molecular docking and dynamic simulation.
    Lu X; Huang A; Xiao M; Sun L; Mao J; Luo G; Xiang H
    Bioorg Chem; 2020 Apr; 97():103666. PubMed ID: 32088420
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In silico discovery and validation of potent small-molecule inhibitors targeting the activation function 2 site of human oestrogen receptor α.
    Singh K; Munuganti RS; Leblanc E; Lin YL; Leung E; Lallous N; Butler M; Cherkasov A; Rennie PS
    Breast Cancer Res; 2015 Feb; 17(1):27. PubMed ID: 25848700
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Wilms' tumor 1 suppressor gene mediates antiestrogen resistance via down-regulation of estrogen receptor-alpha expression in breast cancer cells.
    Han Y; Yang L; Suarez-Saiz F; San-Marina S; Cui J; Minden MD
    Mol Cancer Res; 2008 Aug; 6(8):1347-55. PubMed ID: 18708366
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The terminal substituents of 7α, 6-hexanyl derivatives of estradiol determine their selective estrogen receptor modulator versus agonist activities.
    Hoffman KL; Foster EA; Smith CL
    Steroids; 2012 Apr; 77(5):496-503. PubMed ID: 22326682
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Upregulation of IRS1 Enhances IGF1 Response in Y537S and D538G ESR1 Mutant Breast Cancer Cells.
    Li Z; Levine KM; Bahreini A; Wang P; Chu D; Park BH; Oesterreich S; Lee AV
    Endocrinology; 2018 Jan; 159(1):285-296. PubMed ID: 29029116
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Various phosphorylation pathways, depending on agonist and antagonist binding to endogenous estrogen receptor alpha (ERalpha), differentially affect ERalpha extractability, proteasome-mediated stability, and transcriptional activity in human breast cancer cells.
    Marsaud V; Gougelet A; Maillard S; Renoir JM
    Mol Endocrinol; 2003 Oct; 17(10):2013-27. PubMed ID: 12855746
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Small-molecule "BRCA1-mimetics" are antagonists of estrogen receptor-α.
    Ma Y; Tomita Y; Preet A; Clarke R; Englund E; Grindrod S; Nathan S; De Oliveira E; Brown ML; Rosen EM
    Mol Endocrinol; 2014 Dec; 28(12):1971-86. PubMed ID: 25264941
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Definition of functionally important mechanistic differences among selective estrogen receptor down-regulators.
    Wittmann BM; Sherk A; McDonnell DP
    Cancer Res; 2007 Oct; 67(19):9549-60. PubMed ID: 17909066
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.